Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
Ryan D GentzlerNisha A MohindraShadia I JalalKaren L ReckampRichard D HallNasser H HannaYoung Kwang ChaeMarianna KoczywasIrene B HelenowskiJyoti D PatelPublished in: The oncologist (2023)
Carboplatin, nab-paclitaxel, and pembrolizumab are a safe and effective regimen for patients with both squamous and nonsquamous NSCLC. Although this study did not meet the prespecified endpoints, the median and landmark OS results are consistent with durable benefit of this regimen as seen in phase III trials for first-line treatment of advanced NSCLC.
Keyphrases
- advanced non small cell lung cancer
- phase iii
- open label
- epidermal growth factor receptor
- clinical trial
- phase ii
- double blind
- placebo controlled
- papillary thyroid
- phase ii study
- tyrosine kinase
- small cell lung cancer
- squamous cell
- randomized controlled trial
- squamous cell carcinoma
- study protocol
- radiation therapy
- chemotherapy induced
- rectal cancer